Title
Resistance to single dose albendazole and reinfection with intestinal helminths among children ages 2 to 11 years from the Peruvian Amazon region: a study protocol
Date Issued
01 December 2022
Access level
open access
Resource Type
journal article
Author(s)
Curico G.
García-Bardales P.
Pinedo T.
Shapiama W.
Moncada-Yaicate M.
Romaina L.
Yori P.P.
Oberhelman R.A.
Tulane School of Public Health and Tropical Medicine
University of Virginia
Publisher(s)
BioMed Central Ltd
Abstract
Background: Deworming programs aimed at reducing morbidity and mortality from geohelminth infections are common in many countries where these infections are endemic, but data demonstrating increasing levels of resistance to albendazole and mebendazole are causes for concern. Studies to evaluate the clinical efficacy of deworming programs are critical to maintain high infection control goals. Methods: We propose to assess the clinical efficacy of Peruvian national guidelines for deworming programs in a prospective observational study conducted in the Amazon River basin area near Iquitos, Peru. Major outcomes to be evaluated include (1) albendazole resistance of intestinal helminths (trichuriasis, ascariasis, hookworm), and (2) frequency of reinfection with intestinal helminths 4 months after treatment with albendazole. Children ages 2–11 years from the Belén District of Iquitos will be identified based on a community census. Following parental informed consent, demographic data, weight, and height will be recorded and a stool specimen for parasitological exam by direct observation and Kato-Katz concentration method, and helminthic egg counts will be collected prior to administration of albendazole, following Peruvian national guidelines. Follow-up stool specimens examined in the same manner will be collected at 20 days, 90 days, and 100 days following initial administration of albendazole, and based on parasites found repeat treatment will be administered in accordance with national guidelines. Real-time multiplex qPCR will be performed on helminth positive samples collected prior to initial deworming and on helminth-positive specimens detected on day 15–20. A total sample size of 380 participants was calculated based on total population in the target group and prevalence estimates of helminth infections and clinical resistance based on recent data. Discussion: Data from observational clinical efficacy studies are important to guide geohelminth infection control programs. Trial registrationhttps://www.researchregistry.com/. Identification number: researchregistry7736; Registered retrospectively March 13, 2022; https://www.researchregistry.com/browse-the-registry#home/registrationdetails/622e024cf06132001e3327bf/.
Volume
22
Issue
1
Language
English
OCDE Knowledge area
Gastroenterología, Hepatología
Farmacología, Farmacia
Subjects
Scopus EID
2-s2.0-85131486373
PubMed ID
Source
BMC Infectious Diseases
ISSN of the container
14712334
Sponsor(s)
The study protocol reported in this publication was supported by the Fogarty International Center of the National Institutes of Health under Award Number D43TW010913 entitled “Enabling Infectious Disease Research Capacity in the Peruvian Amazon”. AGL is sponsored by Emerge, the Emerging Diseases Epidemiology Research Training grant D43 TW007393 awarded by the Fogarty International Center of the US National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funder was not involved in the study protocol described here.
Sources of information:
Directorio de Producción Científica
Scopus